Maze Therapeutics
Atul Dandekar is the chief strategy officer of Maze Therapeutics. Atul leads corporate strategy development, product & disease area strategy and portfolio management.
Atul brings more than 20 years of experience in strategy, clinical development and commercialization. Most recently, he was vice president, global franchise head for ophthalmology at Genentech and Roche, where he was responsible for leading the global ophthalmology business. He led the development of the global Roche ophthalmology strategy and led the ophthalmology cross-Roche Team that helped develop faricimab, PDS with ranibizumab and an industry leading retina pipeline. Prior to this role, he led the Phase 3 development programs for faricimab and lampalizumab. Before joining Genentech in 2014, Atul was the senior global program head in neuroscience at Novartis. During his 16-year tenure at Novartis, Atul held roles of increasing responsibility in diverse areas of clinical development, disease area strategy and marketing in India, Australia and Switzerland. Atul is an advisor for the SPARK program at Stanford and a reviewer for Cures within Reach.
Atul holds degrees in medicine and management from Mumbai University and a Master’s in marketing management from Monash University.